- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Florida Cancer Specialists & Research Institute Breast Cancer Partnership Receives National Accreditation
Collaboration with community partners recognized for patient care excellence.
Davenport, Florida — Florida Cancer Specialists & Research Institute (FCS), in collaboration with AdventHealth Heart of Florida and Central Florida Cancer Institute, has received a 3-year accreditation from the National Accreditation Program for Breast Centers, a quality program of the American College of Surgeons.
The breast cancer program received this designation for meeting national standards of excellence for providing comprehensive, patient-centered, multidisciplinary care and demonstrating high-quality clinical outcomes for patients with breast disease.
FCS medical oncologist Swati Pathak, MD said, “We value our partnership with our colleagues to ensure that patients throughout our community have access to a comprehensive range of exceptional care and treatment for breast cancer and other diseases of the breast.”
“This accreditation confirms that our patients consistently receive the highest quality of care, which results in outstanding clinical outcomes,” added Wasif Riaz, MD, FCS medical oncologist. “We are extremely proud.”
Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages
October 31st 2024As health care costs escalate, a new survey reveals that 74% of employers are grappling with the impact on employee wages and benefits, with many anticipating further cost-shifting to their workforce.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
